Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping.

Esmaeili M, Vettukattil R, Bathen TF.

Transl Oncol. 2013 Apr;6(2):92-8. Epub 2013 Apr 1.

2.

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.

Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, Thabet A, Cahill DP, Perry AM, Joseph CP, Muzikansky A, Chi AS.

Oncologist. 2016 Feb;21(2):214-9. doi: 10.1634/theoncologist.2015-0342. Epub 2016 Feb 1.

PMID:
26834160
3.

Magnetic resonance metabolic imaging of glioma.

Metellus P, Figarella-Branger D.

Sci Transl Med. 2012 Jan 11;4(116):116ps1. doi: 10.1126/scitranslmed.3003591.

PMID:
22238331
4.

Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.

Babakoohi S, Lapidus RG, Faramand R, Sausville EA, Emadi A.

Appl Immunohistochem Mol Morphol. 2016 Mar 3. [Epub ahead of print]

PMID:
26945443
5.

Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.

de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB.

Neuro Oncol. 2016 Feb;18(2):283-90. doi: 10.1093/neuonc/nov307. Epub 2015 Dec 20.

PMID:
26691210
6.

The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.

Rakheja D, Medeiros LJ, Bevan S, Chen W.

Front Oncol. 2013 Jul 2;3:169. doi: 10.3389/fonc.2013.00169. eCollection 2013.

7.

Molecular pathogenesis of IDH mutations in gliomas.

Ichimura K.

Brain Tumor Pathol. 2012 Jul;29(3):131-9. doi: 10.1007/s10014-012-0090-4. Epub 2012 Mar 8. Review.

PMID:
22399191
8.

Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas.

Pichumani K, Mashimo T, Baek HM, Ratnakar J, Mickey B, DeBerardinis RJ, Maher EA, Bachoo RM, Malloy CR, Kovacs Z.

Anal Biochem. 2015 Jul 15;481:4-6. doi: 10.1016/j.ab.2015.04.017. Epub 2015 Apr 20.

9.

Glioma-derived mutations in IDH: from mechanism to potential therapy.

Fu Y, Huang R, Du J, Yang R, An N, Liang A.

Biochem Biophys Res Commun. 2010 Jun 25;397(2):127-30. doi: 10.1016/j.bbrc.2010.05.115. Epub 2010 May 27. Review.

PMID:
20510884
10.

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.

Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13.

11.

Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.

Zhu J, Zuo J, Xu Q, Wang X, Wang Z, Zhou D.

Med Hypotheses. 2011 Apr;76(4):602-3. doi: 10.1016/j.mehy.2011.01.011. Epub 2011 Feb 1.

PMID:
21284999
12.

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.

Andronesi OC, Loebel F, Bogner W, MarjaĊ„ska M, Vander Heiden MG, Iafrate AJ, Dietrich J, Batchelor TT, Gerstner ER, Kaelin WG, Chi AS, Rosen BR, Cahill DP.

Clin Cancer Res. 2016 Apr 1;22(7):1632-41. doi: 10.1158/1078-0432.CCR-15-0656. Epub 2015 Nov 3.

PMID:
26534967
13.

IDH mutations in glioma and acute myeloid leukemia.

Dang L, Jin S, Su SM.

Trends Mol Med. 2010 Sep;16(9):387-97. doi: 10.1016/j.molmed.2010.07.002. Epub 2010 Aug 5. Review.

PMID:
20692206
14.

Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.

Weller M, Wick W, von Deimling A.

Glia. 2011 Aug;59(8):1200-4. doi: 10.1002/glia.21130. Epub 2011 Feb 3. Review.

PMID:
21294161
15.

Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells.

Viswanath P, Chaumeil MM, Ronen SM.

Front Oncol. 2016 Mar 14;6:60. doi: 10.3389/fonc.2016.00060. eCollection 2016. Review.

16.

Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.

Gupta R, Webb-Myers R, Flanagan S, Buckland ME.

J Clin Pathol. 2011 Oct;64(10):835-44. doi: 10.1136/jclinpath-2011-200227. Epub 2011 Jul 12. Review.

PMID:
21752797
17.

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.

Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L, Fantin VR, Mak TW.

J Exp Med. 2010 Feb 15;207(2):339-44. doi: 10.1084/jem.20092506. Epub 2010 Feb 8.

18.

Selective detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of glioma patients with mutated Isocitrate Dehydrogenase.

Kalinina J, Ahn J, Devi NS, Wang L, Li Y, Olson JJ, Glantz M, Smith T, Kim E, Giese A, Jensen RL, Chen C, Carter B, Mao H, He M, Van Meir EG.

Clin Cancer Res. 2016 Jun 23. pii: clincanres.2965.2015. [Epub ahead of print]

PMID:
27340277
19.

Metabolic syndromes and malignant transformation: where the twain shall meet.

Bhagwat N, Levine RL.

Sci Transl Med. 2010 Oct 20;2(54):54ps50. doi: 10.1126/scitranslmed.3001669.

PMID:
20962328
20.

MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T.

Bisdas S, Chadzynski GL, Braun C, Schittenhelm J, Skardelly M, Hagberg GE, Ethofer T, Pohmann R, Shajan G, Engelmann J, Tabatabai G, Ziemann U, Ernemann U, Scheffler K.

J Magn Reson Imaging. 2016 Mar 11. doi: 10.1002/jmri.25221. [Epub ahead of print]

PMID:
26970248
Items per page

Supplemental Content

Write to the Help Desk